Abbey International Finance and Ryan Group Holdings have backed Cisiv to scale its operations and enhance its Baseline Plus software.
"We have seen a transformation of the market and a recognition that technology solutions can help deliver evidence more efficiently. We are thrilled to see the uptake of Baseline Plus to enable market access, real-world evidence for health outcomes and patient reported outcomes. This new funding will help us to scale our operations and commercial teams to help deliver real-world data to more life science partners."
The seed round was led by Norrsken VC to help expand the company software for tracking renewable energy sources.
"One of the most effective things anyone can do to reduce their carbon footprint is to purchase energy from carbon-free sources. We’re helping energy companies create more transparent offers for their customers to make switching to clean energy more accessible and more impactful. Consumers deserve to know whether their electricity comes a source that is either destroying our planet or is part of our future."
Sartorius took a minority shareholding in the London startup through its corporate venture unit to support product commercialisation.
"The SPARTA platform will help customers optimize the design of nanoparticles at an early stage, even before the drug candidates move on to the clinic. We have teamed up to bring additional product commercialization and application expertise to the table to facilitate a swift transitioning from prototype to launch,"
— Oscar-Werner Reif, Head of Corporate Research and CTO
Calculus Capital led the financing round alongside several institutional investors to support platform development and pipeline progression.
"GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments."
